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ABSTRACT
Since 1998, the National Comprehensive Cancer Network (NCCN) guidelines have
specified clinical indications for genetic testing for breast cancer susceptibility genes, but
retrospective studies have shown that, despite meeting the NCCN criteria, patients are not
always advised of the option of genetic testing. Further compounding this issue, studies
have shown that cancer family history intake and documented family history can be
incomplete even when taken by oncology providers. At this study site and other cancer
centers in the country, patients with a new diagnosis of breast cancer are referred for genetic
counseling by their cancer care team if they are deemed to meet NCCN criteria for genetic
testing. For this study, the authors sought to explore if a family history, as gathered by a
genetic counselor, will find additional patients who meet these criteria. Patients with a new
diagnosis of breast cancer who were not referred for genetic counseling and testing were
contacted and randomized to have their personal and family history collected via telephone
or online questionnaire. Of the 64 patients contacted, 40 provided complete information
about their personal and family history. The response rate was higher for the patients
offered a pedigree assessment via phone (65.6%, n=21) compared to those offered the
questionnaire (59.4%, n=19). In total, 11 (27.5%) individuals were found to meet NCCN
criteria after the additional assessment—seven were detected by pedigree and four by
online questionnaire. Of note, three of these patients were referred by their oncologist after
consultation but prior to notification from the study team, meaning they were ultimately
identified by the current system. Furthermore, two of the 11 patients did not meet
iv

criteria after first contact with the genetic counseling team but met criteria after new
information was obtained from discussions with relatives. The most common cancers in a
family history that were overlooked by previous provider intake were pancreatic cancer
(n=4) and prostate cancer (n=3). Since these two cancer types have been added to
guidelines more recently, this indicates a need for better provider education following
guideline updates. Adding a family history assessment tool to assist with identification of
these patients is another avenue for exploration. However, when considering method of
assessing patients, it is important to consider patients likelihood to respond. Further studies
can build upon the data from this study to assess success of interventions and impact on
patient care.
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CHAPTER 1
BACKGROUND AND LITERATURE REVIEW

1

1.1 Hereditary Breast Cancer
Most cancers are considered sporadic in origin, but approximately 5-10% of
cancers are caused by an inherited susceptibility (Garber & Offit, 2005; Lynch et al., 1995).
Hereditary cancer syndromes consist of an increased risk for certain types of cancer and
are caused by mutations in specific genes. For example, inherited mutations in the BRCA1
and BRCA2 genes are associated with Hereditary Breast and Ovarian Cancer syndrome
(HBOC), which is characterized by an increased lifetime risk for breast and ovarian cancer
as well as prostate and pancreatic cancer. Because these genetic syndromes have known
cancer risks, changes in medical management are recommended to either reduce the risk
of cancer or increase early detection.
Mutations in BRCA1 and BRCA2 make up about 30% of hereditary breast cancer
(Couch et al., 2017). The general population risk for breast cancer is roughly 12%, but
mutations in BRCA1 and BRCA2 can increase the lifetime breast cancer risk to 69-72%
(Anglian Breast Cancer Study Group, 2000; Antoniou et al., 2003; Chen & Parmigiani,
2007; Ford, 1994; Hu et al. 2020; King et al., 2003; Kuchenbaecker et al, 2017; Mavaddat
et al., 2013; Risch et al., 2006; Van den Broek et al, 2016). In addition to female breast
cancer, risks associated with mutations in BRCA1 and BRCA2 include a 10% lifetime risk
for male breast cancer, a 16.5-40% ovarian cancer risk, a prostate cancer risk of 8.6-20%,
a 5-10% risk for pancreatic cancer, and an increased chance of developing melanoma with
a mutation in BRCA2 (Petrucelli et al, 2016).
The BRCA1 and BRCA2 genes code for proteins that are part of the Fanconi
anemia/BRCA (FA-BRCA) pathway which is involved in homologous recombination
repair of DNA double-strand breaks. Mutations in the BRCA1 and BRCA2 genes result in
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a defect in the repair mechanism leading to an accumulation of somatic cancer-causing
mutations (Royfman et al., 2021).
While the BRCA1 and BRCA2 genes are among the most well-characterized breast
cancer genes, over 20 genes have been associated with an increased lifetime risk for breast
cancer including CDH1, PALB2, PTEN, and TP53. A mutation in CDH1 increases the risk
for diffuse gastric cancer as well as lobular breast cancer (Shenoy, 2019). Mutations in the
PALB2 gene, which is also part of the FA-BRCA pathway, result in an increased lifetime
risk for breast cancer to 41-60%, ovarian cancer to 3-5%, and pancreatic cancer to 5-10%
(Nepomuceno et al., 2021). PTEN, another tumor suppressor gene, is involved in cell cycle
regulation, cell growth, and proliferation (Hopkins et al., 2014). Mutations in PTEN can
increase the lifetime risk for breast cancer to 85% in females, as well as an increased
lifetime risk for thyroid cancer (21-35%), renal cell cancer (15-35%), uterine cancer (1928%), colon cancer (9-16%), and melanoma (5%). Finally, TP53 is a tumor suppressor
gene involved in controlling the cell cycle and apoptosis (Schneider et al., 2019). An
inherited mutation in TP53 results in an overall increase in an individual’s lifetime risk for
cancer, with the risk for cancer in men being at least 70% and at least 90% in women. The
five cancers that are most commonly observed in individuals with TP53 mutations are
breast, brain, adrenocortical carcinomas, leukemia and sarcomas.
The National Comprehensive Cancer Network (NCCN), a nonprofit network of
cancer centers throughout the United States, publishes treatment, screening, and diagnosis
guidelines for many types of cancer. These guidelines include criteria for germline genetic
testing as well as management and screening recommendations for individuals with a
known mutation in a hereditary cancer gene. The NCCN guidelines for Genetic/Familial
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High-Risk Assessment: Breast, Ovarian, and Pancreatic suggest genetic testing is clinically
indicated for specific individuals with breast cancer (National Comprehensive Cancer
Network [NCCN], 2021).The guidelines specifically target BRCA1, BRCA2, CDH1,
PALB2, PTEN, and TP53, a group of high-penetrance breast susceptibility genes.
According to these guidelines, additional hereditary cancer genes can be included in a
genetic test, but these genes have moderate penetrance. NCCN does not currently endorse
for or against the inclusion of these moderate penetrance genes. The 2021 NCCN
guidelines for genetic testing of individuals with a personal history of breast cancer are:
Table 1.1 NCCN Testing Criteria of High-Penetrance Breast Cancer Susceptibility
Genes (Specifically BRAC1, BRAC2, CDH1, PALB2, PTEN, and TP53)
Personal history of breast cancer and…
Triple-negative breast cancer
Ashkenazi Jewish ancestry
≤ 45 years
46-50 years and
Unknown or limited family history
Multiple primary breast cancers (synchronous or metachronous)
≥ 1 close blood relative with breast, ovarian, pancreatic or prostate cancer
at any age
≥ 51 years and
≥ 1 close blood relative with any:
Breast cancer at age ≤50 year or male breast cancer at any age
Ovarian cancer at any age
Metastatic, intraductal/cribriform histology, or high- or very- high
risk group prostate cancer at any age
≥ 3 total diagnoses of breast cancer in patient and/or close blood relatives
≥ 2 close blood relatives with either breast or prostate cancer (any grade)
at any age

Because the cancer risk for individuals with mutations in these hereditary cancer
genes is higher than the general population risk, the management recommendations for
these individuals are also more intensive than the general population recommendations.
The goal of increased screenings is to detect cancers earlier so that they are easier to treat.
Identification of an individual with a mutation in a hereditary cancer gene can lead not only
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to early detection but to personalization of care for the individual and other members in the
family (Tischler et al., 2019).
The NCCN guidelines for Genetic/Familial High-Risk Assessment: Breast,
Ovarian, and Pancreatic suggest managing breast cancer risk associated with a BRCA1 and
BRCA2 mutation by starting annual breast MRI at age 25 and adding annual mammogram
at the age of 30 compared to the average risk recommendation of starting annual
mammogram at age 40 and having no additional routine imaging. Additionally, these
management guidelines include the option of a risk-reducing mastectomy for BRCA1 and
BRCA2 mutation-carrier women, replacing the need for frequent imaging. To manage the
elevated ovarian cancer risk, women are recommended to have a bilateral risk-reducing
salpingo-oophorectomy following the completion of childbearing. Guidance for men is
also included in these guidelines, and pancreatic screening is recommended for both men
and women in the presence of a family history of pancreatic cancer in a first or second
degree relative (NCCN, 2021). NCCN provides guidance for the other high-risk genes as
well with management recommendations reflecting cancer risks and age when those
cancers have been shown to develop.
1.2 NCCN Impact on Care
The NCCN first added genetic testing criteria to their management
recommendations in 1998 and the recommendations have changed over time due to
advances in genetic testing technology and an increased understanding of hereditary cancer
predispositions (Alberty-Oller et al., 2021; Beitsch et al., 2019).
Alberty-Oller et al. (2021) used chart review to assess how many patients meeting
NCCN criteria were referred to genetics at the Tisch Cancer Institute at Mount Sinai
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Hospital. This retrospective chart review included patients with a diagnosis of invasive
breast cancer assessed medical and family history to determine if the patients met NCCN
criteria. The researchers found that 21% (45/212) met criteria but were not referred to
genetic counseling. For this study, referral to genetic counseling included a conversation
about genetics documented by the referring physician and a consultation note by a genetic
counselor in the medical record. Of the individuals that were not referred despite meeting
criteria, 41 out of 45 had met criteria based on family history, rather than personal factors
(Alberty-Oller at al., 2021).
Childers et al. (2017) reviewed the National Health Interview Surveys (NHIS) from
2005, 2010, and 2015. The survey assessed if individuals with a history of breast and/or
ovarian cancer had a conversation about genetics with their doctor, were advised to have
genetic testing, and/or had genetic testing. Medical and family history from the NHIS were
used to see if patients met 2017 NCCN criteria. The researchers found fewer than 1 in every
5 individuals who met NCCN criteria for genetic testing had the testing performed and
81% had never discussed genetic testing with their healthcare provider (Childers et al.,
2017).
Several studies have evaluated effectiveness of NCCN guidelines’ identification
of individuals that would have benefited from genetic testing. Cropper et al. (2017)
reviewed charts of 1,123 patients with breast cancer seen from March 31, 2013 through
June 30, 2014, at the University of Texas MD Anderson Cancer Center. The patient’s
medical and family history were reviewed to determine which and how many of the NCCN
criteria were met. This study showed that the diagnostic yield was higher when individuals
met several NCCN criteria, compared to those that only met criteria due to a diagnosis of
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breast cancer prior to age 45. In this study, 329 patients only met one criterion and 11
(3.3%) of these were found to be BRCA1 and BRCA2 positive. This was compared to the
644 individuals that met two or more criteria; 88 (13.7%) of these were found to be BRCA1
or BRCA2 positive (Cropper et al., 2017). Manickam et al. (2018) used cross-sectional
analysis of individuals who volunteered for Geisinger’s MyCode healthy genome study.
Through exome sequencing of 50,726 samples, 267 samples were found to be carriers of a
BRCA1 and BRCA2 mutation. Analysis of 122 pedigrees of BRCA1 or BRCA2 carriers
revealed 63% (77/122) met NCCN criteria. Of the 89 individuals with a mutation in BRCA1
and BRCA2 who had not previously had genetic testing, 45 (50.5%) met NCCN criteria,
while 44 individuals did not. These 44 individuals would not have been offered testing
outside of this study because their family history was not concerning for hereditary cancer
(Manickam et al., 2018).
Beitsch et al. (2019) conducted a multicenter prospective study of individuals with
a recent or past diagnosis of breast cancer who had not previously undergone genetic
testing. These patients were divided into two equal cohorts, those who met the 2017 NCCN
guidelines for genetic testing and those who did not. The results showed the overall
positivity rate on a multigene panel of 80 genes was 8.65% (83/959). The overall positivity
rate for those that met NCCN criteria was 9.39% (45/479), while the overall positivity rate
was 7.9% (38/480) for the participants that did not meet NCCN criteria. Although, when
only considering BRCA1 and BRCA2, the positivity rate of the patients that met criteria
was four-fold of those who did not. When looking more closely at the individual genes that
were found to have mutations, there was a higher rate of reduced penetrance genes in the
group that did not meet criteria. For example, eight individuals tested positive for a single
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pathogenic variant in MUTYH, which may increase the chance for colon cancer or breast
cancer, but the data is not strong at this time (Beitsch et al., 2019; NCCN, 2021). Mutations
in ATM and CHEK2 were also detected more in the group that did not meet criteria (Beitsch
et al., 2019). Both the ATM and CHEK2 genes are considered reduced penetrance, and
screening recommendations for cancers associated with ATM and CHEK2 are less welldefined.
1.3 Role of Family History
As stated in the testing criteria, family history is an important tool in determining
who meets current criteria for genetic testing. Genetic counselors annotate important
genetic family history information into a pedigree, which is a visual representation of the
family and the medical and biological relationships between individuals in the family. A
pedigree provides a concise family and medical history summary with the important
information easily obtainable in a glance (Bennett, 2010). A cancer-focused pedigree
consists of three to four generations including both the maternal and paternal sides
(Schneider, 2012). Cancer information is recorded including type of cancer, age at
diagnosis, and treatment. The pedigree should include all individuals’ current age or age
of death, as well as the cause of death, regardless of reason.
A study conducted by Sussner et al. (2011) at Mount Sinai School of Medicine
surveyed primary care providers (PCPs) including physicians and nurse practitioners (NPs)
working in general medicine and obstetrics/gynecology (ob/gyn). This study identified that
25% of PCPs asked patients about cancer history in first- and second-degree relatives on
both sides of the family, including type of cancer and age of diagnosis, to assess for
hereditary cancer risk. They also assessed provider’s confidence in making appropriate
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genetic counseling referrals and their perceived skill level to conduct their own counseling
about genetic testing. The group with the highest reported confidence was the ob/gyns and
the lowest was NPs. Overall, 1.7% of providers perceived themselves as experts when it
came to interpreting cancer risk based on family history (Sussner et al., 2011).
Studies have shown that oncologists are more familiar with breast cancer genetics
than ob/gyns and general medicine physicians (Doksum et al., 2003). However, the quality
of the family history recorded by oncologists through chart review was often incomplete
(Jones et al., 2020; Wood et al., 2014). In Jones et al. (2020), 80% of the family histories
contained only first-degree relatives (parents, siblings) and only 3% of patients had thirddegree relatives (first cousins) documented on the pedigree. Wood et al. (2014) showed
that of the patients who had cancer, 79.8% had a first-degree relative and 64.6% had a
second-degree relative documented in their medical record. Depending on cancer type, the
quality of family history documented in the chart differed significantly. For example,
family histories for colorectal cancer were more likely to be incomplete. Fewer pedigrees
included first- and second-degree relatives, and ages of diagnosis were missing for family
members with a cancer diagnosis. This study also showed that of the people that met NCCN
criteria for genetic counseling and genetic testing, 43% were referred for genetic
counseling. The referral rate was higher for breast cancer compared to colorectal cancer
(Wood et al., 2014).
Providers have expressed interest in tools to help assist in gathering family history
information and studies have found that patients would like to have more time to gather
the information about their family history prior to the appointment (Nathan et al., 2016;
Sussner et al., 2011). Family history tools can serve as a prompt for the patient to know
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what history is relevant (Hallowell et al., 1997; Pritzlaff et al., 2014). These tools can be in
the form of paper family history questionnaires that are mailed or securely sent to the
patient through the electronic medical record (EMR). There is also online software that
asks family history questions and creates a pedigree based on the patient’s answers. Studies
have found these tools are an efficient and accurate way to help triage patients and provide
adequate time for patients to obtain information from their family members (Armel et al.,
2009; Vogel et al., 2012). Pritzlaff et al. (2014) studied the use of an online family history
tool and found that it decreased the genetic counselor’s time spent taking the family history
by half. While there seems to be high satisfaction and efficacy with these tools, only 52.3%
of individuals completed the questionnaire (Prizlaff et al., 2014). Previous studies have
revealed that this low response rate could be due to several factors including familiarity
with family history, being busy, procrastinating or forgetting, not receiving the mailed
questionnaire, feeling overwhelmed or confused, age, and race (Appleby-Tagoe et al.,
2012; Armel et al., 2011; Pritzlaff et al., 2014). Also, response rates differed between racial
background as Native Hawaiian and Pacific Islanders (8.3%) were least likely to complete
the form, while white (55.2%), Native American (53.3%), and Asian (52.6%) individuals
were more likely to complete the questionnaire. Individuals with private insurance were
more likely to complete the questionnaire than those with public insurance (Pritzlaff et al.,
2014).
1.4 Rationale of Study
According to the literature, documentation of family cancer history is often
incomplete, affecting ability to assess whether a patient meets NCCN guidelines for genetic
testing. This means there may be patients that could benefit from a genetics evaluation and
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testing that are not currently being identified. This study will provide an assessment of
current identification of patients appropriate for genetic counseling and determine if more
patients with a new breast cancer diagnosis meet criteria for referral than are currently
being identified.
1.5 Objectives
1. Determine if a more thorough family history, such as that taken during a genetic
counseling session, would capture more patients appropriate for referral to genetic
counseling.
2. Evaluate two methods of gathering additional family history—phone call or online
questionnaire—to determine effectiveness of each in identifying additional patients
meeting criteria for referral for genetic counseling and testing.
1.6 Hypothesis
NCCN criteria for genetic counseling and testing have expanded, and there are
likely more individuals who meet these criteria than may be identified by a limited nongenetics provider’s intake of cancer family history. It is expected that a thorough family
history, as gathered by a genetic counseling intern, will identify additional individuals who
meet criteria for a referral for genetic counseling and testing.

11

CHAPTER 2
ASSESSING IDENTIFICATION OF NEWLY DIAGNOSED BREAST CANCER
PATIENTS FOR REFERRAL TO GENETIC COUNSELING 1

1

Locke, C., Whitlock, S., Say, C., Parker, H. & Dobek, W. To be submitted to the Journal of Clinical
Oncology
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2.1 Abstract
Since 1998, the National Comprehensive Cancer Network (NCCN) guidelines have
specified clinical indications for genetic testing for breast cancer susceptibility genes, but
retrospective studies have shown that, despite meeting the NCCN criteria, patients are not
always advised of the option of genetic testing. Further compounding this issue, studies
have shown that cancer family history intake and documented family history can be
incomplete even when taken by oncology providers. At this study site and other cancer
centers in the country, patients with a new diagnosis of breast cancer are referred for genetic
counseling by their cancer care team if they are deemed to meet NCCN criteria for genetic
testing. For this study, the authors sought to explore if a family history, as gathered by a
genetic counselor, will find additional patients who meet these criteria. Patients with a new
diagnosis of breast cancer who were not referred for genetic counseling and testing were
contacted and randomized to have their personal and family history collected via telephone
or online questionnaire. Of the 64 patients contacted, 40 provided complete information
about their personal and family history. The response rate was higher for the patients
offered a pedigree assessment via phone (65.6%, n=21) compared to those offered the
questionnaire (59.4%, n=19). In total, 11 (27.5%) individuals were found to meet NCCN
criteria after the additional assessment—seven were detected by pedigree and four by
online questionnaire. Of note, three of these patients were referred by their oncologist after
consultation but prior to notification from the study team, meaning they were ultimately
identified by the current system. Furthermore, two of the 11 patients did not meet

criteria after first contact with the genetic counseling team but met criteria after new
information was obtained from discussions with relatives. The most common cancers in a
family history that were overlooked by previous provider intake were pancreatic cancer
(n=4) and prostate cancer (n=3). Since these two cancer types have been added to
guidelines more recently, this indicates a need for better provider education following
guideline updates. Adding a family history assessment tool to assist with identification of
these patients is another avenue for exploration. However, when considering method of
assessing patients, it is important to consider patients likelihood to respond. Further
studies can build upon the data from this study to assess success of interventions and
impact on patient care.
2.2 Introduction
Hereditary cancer accounts for 5-10 % of all cancer (Garber & Offit, 2005; Lynch
et al., 1995). Breast cancer is found to be hereditary in up to 10% of cases (Childers et al.,
2017). The National Comprehensive Cancer Network (NCCN) publishes guidelines for
Table 2.1 NCCN Testing Criteria of High-Penetrance Breast Cancer Susceptibility
Genes (Specifically BRAC1, BRAC2, CDH1, PALB2, PTEN, and TP53)
Personal history of breast cancer and…
Triple-negative breast cancer
Ashkenazi Jewish ancestry
≤ 45 years
46-50 years and
Unknown or limited family history
Multiple primary breast cancers (synchronous or metachronous)
≥ 1 close blood relative with breast, ovarian, pancreatic or prostate cancer at
any age
≥ 51 years and
≥ 1 close blood relative with any:
Breast cancer at age ≤50 year or male breast cancer at any age
Ovarian cancer at any age
Metastatic, intraductal/cribriform histology, or high- or very- high risk
group prostate cancer at any age
≥ 3 total diagnoses of breast cancer in patient and/or close blood relatives
≥ 2 close blood relatives with either breast or prostate cancer (any grade) at any
age
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genetic testing in specific individuals with breast cancer as well as management for those
found to have a hereditary cancer syndrome (Table 2.1). The guidelines recommend a
thorough evaluation of both personal and family history to determine if genetic testing is
appropriate. The NCCN guidelines have become more widely utilized, but patients that
may benefit from a genetics evaluation can still be missed in routine clinical practice when
family history intake is less thorough (Alberty-Oller et al., 2021).
Alberty-Oller et al. (2021) used retrospective chart review of patients with a
diagnosis of invasive breast cancer and found 21% (45/212) met NCCN criteria but were
not referred to genetics. Of the individuals that were not referred despite meeting criteria,
41 out of 45 met criteria based on family history, rather than personal, factors (AlbertyOller et al., 2021).
Similarly, Childers et al. (2017), in a review of the medical and family history from
the National Health Interview Surveys (NHIS) found that fewer than 1 in every 5
individuals who met NCCN criteria for genetic testing had the testing performed and 81%
had never discussed genetic testing with their healthcare provider.
Family history is an important tool in assessing cancer risk (Alberty-Oller et al.,
2021; Childers et al., 2017). Family histories to assess this risk should include three to four
generations, including first-, second- and third- degree relatives and have age of cancer
diagnosis as well as current age or age of death. Despite the role it plays in determining
cancer risk, family histories have been found to be incomplete when taken by non-genetic
providers (Doksum et al., 2003; Jones et al., 2020; Sussner et al., 2011; Wood et al., 2014;).
Studies have shown that oncologists are more familiar with breast cancer genetics than
obstetricians/gynecologists (ob/gyns) and general medicine physicians (Doksum et al.,
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2003). However, in Jones et al. (2020), 80% of the family histories contained only firstdegree relatives and 3% of patients had third-degree relatives documented on the pedigree.
Wood et al. (2014) showed that, of the patients who had cancer, 79.8% had a first-degree
relative and 64.6% had a second-degree relative documented in their medical record.
Depending on cancer type, the quality of family history documented in the chart differed
significantly. For example, family histories for individuals with colorectal cancer were
more likely to be incomplete; fewer pedigrees included first- and second-degree relatives
documented, and ages of diagnosis were missing for family members with a cancer
diagnosis. This study also showed that, of the people who met NCCN criteria for genetic
counseling and genetic testing, 43% were referred for genetic counseling. The referral rate
was higher for breast cancer compared to colorectal cancer (Wood et al., 2014).
Tools have been developed to aid in the process of collecting complete family
histories such as questionnaires targeting the NCCN genetic testing criteria. Both providers
and patients find completing a questionnaire ahead of time beneficial (Armel et al., 2009;
Hallowell et al., 1997; Nathan et al, 2016; Pritzlaff et al., 2014; Sussner et al., 2011; Vogel
et al., 2012). Studies have shown that providers believe that questionnaires aid in efficiency
and help guide patients to relevant information and helps triage referrals. Patients benefit
from time to gather the necessary information about their family prior to their visit and
know what information is important.
This study explored the effectiveness of the current family history screening at one
cancer center in Columbia, South Carolina and compared the utility of an online
questionnaire based on NCCN guidelines compared to a family history taken by a genetic
counseling intern on the telephone. NCCN criteria for genetic counseling and testing have
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expanded and there is concern that individuals who meet these criteria are overlooked by
limited cancer family history intake. It was expected that a family history, as gathered by
a genetic counseling intern, would identify additional individuals who meet criteria for a
referral for genetic counseling and testing.
2.3 Materials and Methods
This study was conducted at Prisma Health-Midlands in Columbia, South Carolina
from September 2021 to February 2022. Participants in this study were women with a new
diagnosis of breast cancer. Traditionally, at this center, a patient’s surgeon, oncologist,
and/or nurse navigator inquire about a family history of cancer throughout the patient’s
breast cancer treatment. After presentation at breast conference of the patient’s personal
and collected family history, typically including the history taken by the nurse navigator
and surgeon, it is determined if the patient meets NCCN criteria for genetic testing. Patients
that meet current NCCN guidelines for genetic testing are referred for a genetic counseling
appointment.
All patients diagnosed with breast cancer received communication from the nurse
navigator after their diagnosis. During this initial phone call, the nurse navigator prepares
patients for what they can expect in the coming weeks, including genetic counseling. The
patients are then presented at breast conference for multidisciplinary input on the patient’s
treatment plan, including and if they require a genetic counseling referral. For those that
did not meet criteria from the history reported at breast conference, a phone call from the
genetic counseling office served as the notification for the opportunity to be assessed for
appropriateness of a genetic counseling referral. Patients were randomized to receive an
online questionnaire about their family history or a phone call to collect their family
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history. Patients were assigned a questionnaire or phone call based on the order they were
presented at the conference. Patients were able to decline to share additional information
about their family history. Family history gathered by phone followed guidance in Forman
and Schwartz (2019) and National Institutes of Health consensus statement (Lu et al.,
2014). The online questionnaire was designed by the genetic counselors and collected
information about cancer in the family specifically targeted to the NCCN criteria. To
increase the yield of completed online questionnaires, the genetic counseling office
recontacted patients who had not responded and offered to complete the questionnaire over
the telephone. Throughout this study, patient information used and stored was de-identified
by using the case number given to patients at breast conference. All identifying information
was stored in a secure, password-protected database. For those participants that met NCCN
criteria for genetic testing after the pedigree or online survey, their providers were informed
by a genetic counselor employed at Prisma Health through the electronic medical record
(EMR) about the recommendation for a genetic counseling referral. Those who did not
meet criteria also had a note placed in the EMR stating such.
This study was reviewed by Prisma Health IRB and was determined to not be
research that required IRB approval.
2.3.1 Statistical Analysis
Descriptive statistics were used to highlight effects on genetic counseling referrals
and describe trends in patients not initially targeted for referral. While one of the original
objectives was to compare the two methods of data collection (phone call and online
questionnaire), there was not a sufficient sample size to conduct statistical comparisons.
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2.4 Results
2.4.1 Participants
There were 186 individuals with breast cancer presented during breast conference
at Prisma Health-Midlands from September 2021 through February 2022. Of the 186,
65.5% (122/186) were determined to meet criteria for genetic testing at breast conference.
The other 64 were contacted as part of this study; 24 were unable to be reached and did not
return calls. The other 40 patients had their family history collected and reviewed.

Figure 2.1 Participant ascertainment
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Table 2.2 Demographics (N=40)
Age

Race

Age Range
50-59
60-69
70-79
80-89
90-99

Total
13 (32.5%)
9 (22.5%)
13 (32.5%)
4 (10%)
1 (2.5%)

American Indian/Alaska Native

2 (5%)

Black or African American
White

14 (35%)
24 (60%)

Hispanic or Latino
Not Hispanic or Latino
Unknown/ Not reported

1 (2.5%)
37 (92.5%)
2 (5%)

Ethnicity

2.4.3 Comparing Tools
The response rate for the phone call was 65.6% (21/32). The initial response rate to
the online questionnaire was 31.3% (10/32). An additional nine questionnaires were
completed over the phone with the assistance of the genetic counseling office to bring the
final completed questionnaire rate to 59.4% (19/32). Seven individuals met criteria after
family history collection by a genetic counseling intern and four met criteria after
completion of the online questionnaire (by either the patient or assistance of the genetic
counseling intern). Because of the small sample size, we were not able to determine if
methodology of gathering the family history made a statistically significant difference in
identification for referral to genetic counseling. Figure 2.2 demonstrates the differences in
response rate between tools.
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Figure 2.2 Contact methods and response rate

2.4.2 Identification for Referral
Of the 40 total participants, 11 (27.5%) were found to meet NCCN criteria after
intervention. Statistical significance could not be determined due to small sample size. Data
was collected on the individual’s family history that was not noted during the initial intake
of the affected patient. Most commonly, as shown in Figure 2.3, a family history of cancer
was missed rather than personal characteristics. Personal characteristics include
information about the patient’s personal history that allows them to meet NCCN criteria
(e.g. triple negative cancer, diagnosed at age 45 or younger, Ashkenazi Jewish ancestry)
and family characteristics are items other than history of cancer such as an unknown or
limited family history. Pancreatic (n=4) and prostate (n=3) cancers were the most common
relevant family history that was not noted by the patient’s initial intake.
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4
3
2
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Figure 2.3 Relevant personal or family history in patients not referred on initial intake
(N=11)
Three individuals who were not identified at breast conference as needing a referral
were seen for genetic counseling following their consultation with their oncologist. For
these patients, their oncologist correctly identified that they met NCCN criteria, and they
were seen by genetic counseling prior to notification from the genetic counseling team
working on this project. One of these individuals had triple negative breast cancer, one was
found to have a family history of ovarian cancer, and the third had a more extensive family
history of breast cancer than originally noted. After removing these patients from the study
group as they were eventually identified by a healthcare provider, 21.1% (8/38) were only
identified for genetic counseling after intervention by the genetic counseling team. Out of
these nine remaining individuals, two went to their family and gathered more information
following the phone call or online questionnaire. They recontacted the study team to update
their history and were found to meet criteria at that time.
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2.5 Discussion
Of the newly diagnosed breast cancer patients that were not identified upon initial
intake, 27.5% met NCCN criteria upon review of their personal and family history by a
genetics professional. This shows there are qualifying individuals that are not offered a
genetic counseling referral. The most frequent missed cancer type in the family history was
pancreatic followed by prostate. Only one of the individuals missed had a family history
of breast cancer that met NCCN criteria, suggesting providers may be more likely to
directly ask about family history of breast cancer compared to the other cancers. This could
be because pancreatic cancer was first included in the NCCN guidelines in 2019, which is
relatively more recent than other recommendations (Tempero, 2019). The most recent
NCCN guidelines expanded testing criteria to include any close relative with prostate
cancer for individuals diagnosed with breast cancer from 46-50 years of age, regardless of
the features of this prostate cancer. Previously, prostate cancer had to be metastatic cancer
(or Gleason score ≥ 7) to contribute towards the patient meeting NCCN guidelines
regardless of age of breast cancer diagnosis. This most recent change may account for the
limited identification of prostate cancer in family histories. Since the sample size in this
study was small, it is difficult to determine if there would be a continuation of this trend in
a larger sample size.
Two individuals that were not identified at breast conference as needing a referral
were later referred for genetic counseling following their consultation with their oncologist.
One of these individuals was found to have triple negative breast cancer shortly after the
NCCN guidelines were updated in August 2021 to include all individuals with triple
negative breast cancer. Previously, only individuals diagnosed with triple negative breast
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cancer at less than 60 years of age met NCCN criteria for genetic testing. These findings
support the need for genetic counselors to continue to stay up to date with the most current
NCCN guidelines and provide that information to other providers as a valued member of
the breast cancer care team.
Of the other individuals later referred to genetic counseling, one was found to have
a family history of ovarian cancer and the other had breast cancer in a third-degree relative.
Previous studies have shown oncologists are more familiar with NCCN guidelines than
other providers (Doksum et al, 2003; Jones et al., 2020; Wood et al., 2014;). Though we
were unable to determine if this trend would continue with a larger sample size, it seems
that oncologists were more familiar with what family history and what degree of family
history was important.
Two of the patients contacted during the study were found not to meet criteria when
their family history was first taken. However, they recontacted the genetics office after the
evaluation with additional family history information that led to them meeting NCCN
criteria. This suggests that individuals may need prompting to know what questions to ask
of their family members. Patients should also be encouraged to update their history with
their medical team. Studies have found that tools, such as questionnaires or online
platforms, are an efficient and accurate way to help triage patients and provide adequate
time for patients to obtain information from their family members (Armel et al., 2009;
Vogel et al., 2012).
The response rate was higher for phone pedigree compared to the online
questionnaire. Several conclusions can be considered from this point. Multiple steps are
involved in completing an online questionnaire compared to answering questions during a
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phone call. Patients who had the online questionnaire had to look in their email for the
invitation to complete the survey and then take the time to fill it out. Only one patient
started the survey and did not complete it. Patients who were assigned a questionnaire and
had not completed it were recontacted. To remove barriers and increase completion rate,
the surveys were completed over the phone if the patient was reached. Through this
process, an additional nine questionnaires were completed. No new patients completed the
questionnaire after receiving a voicemail reminding them of the questionnaire. The
response rate was closer to the pedigree response rate after the genetic counseling office
recontacted patients. A response rate around 50% is consistent with other studies looking
at utility of family history tools that similarly use online platforms (Armel et al., 2011;
Pritzlaff et al., 2014). Unfortunately, there is a lack of data of how to increase the response
rate because the individuals who do not respond are difficult to access (Armel et al., 2011).
While patients were captured using both methods of contact, taking a complete
pedigree takes more time than the questionnaire. Pedigrees typically took 15 to 20 minutes
to collect, putting a time burden on both the provider and the patient. Currently, it would
not be practical for genetic counselors to contact every patient with a new diagnosis of
breast cancer at this institution. The low initial response to the online questionnaire also
puts in question the utility of that tool for this population. Because of both of these
concerns, other routes of intervention may be preferred such as adding a tool to the
physicians’ practices to aid in identification. This may take the form of a questionnaire sent
out via the EMR or a questionnaire while waiting on the appointment with their physician.
Both methods could have a benefit over the emailed questionnaire sent in this study, since
emails, especially those not associated with the physician’s office, may be overlooked.
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It will also be important to track the genetic testing results in the 11 patients who
were recommended to seek genetic counseling as a result of this study. If the results show
that genetic testing would have changed medical management through a positive genetic
test result, then that further supports the importance of considering intervention and future
implementation of such tools. Studies have shown 10-12% of individuals who meet NCCN
guidelines have a positive genetic testing result that will impact management (Kurian et
al., 2018; Couch et al., 2017).
2.5.1 Study Limitations
The small sample size was a limitation for this study. We were unable to determine
if age of the patient, their race, and/or what cancers in the family could have contributed to
the identification for genetic counseling referral. It is also unclear why there was a low
initial questionnaire response compared to taking a family history over the phone. This
study’s response rate was lower than the 50% seen in other studies regarding electronic
family history questionnaires (Armel et al., 2009; Armel et al., 2011; Pritzlaff et al., 2014).
This could be due to these tools being used prior to genetic counseling appointments. Both
studies by Armel et al. (2009, 2011) required a completed family history questionnaire
prior to scheduling a genetic counseling appointment. The patients in these studies may
have a higher perceived risk and motivation than patients determined not to need genetic
counseling by their other medical providers.
2.5.2 Future Directions
Future studies need to be done to understand why some patients are not being
identified as appropriate for genetic counseling referral. Continuing data collection over
several years would allow for an increase in the sample size to determine broader trends.
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A future study could utilize an intervention, such as a review of NCCN guidelines with the
breast care team, followed by a similar review of rates of identification and referral to
genetic counseling.
Future studies could also assess the success of another implemented family history
tool such as an EMR questionnaire or physical form in the surgeon’s office. This study's
questionnaire was not validated. Studies of the accuracy of questionnaires used to take
family histories showed 92% of the pedigrees required changes when reviewed with a
genetic counselor (Armel et al., 2009). To assess the accuracy of the survey tool, it would
be beneficial to review the pedigrees taken during the genetic counseling session of those
who met NCCN guidelines via the questionnaire.

15

CHAPTER 3
CONCLUSIONS
This study evaluated if all women with a new diagnosis of breast cancer at Prisma
Health-Midlands were being appropriately identified for referral to genetic counseling.
Patients who were determined to not meet NCCN criteria after initial presentation at breast
conference were contacted by a genetic counseling intern to review their family history.
We also explored the use of an alternate tool to taking a full family history via an electronic
questionnaire based on the current NCCN guidelines. The sample size was too small to
determine statistical significance of referral rates, but we did identify 11 patients (27.5%)
who were missed during the breast conference that ultimately did meet criteria for genetic
testing. The most common missed criteria were a family history of pancreatic cancer or
prostate cancer. The number of patients found to meet criteria is indicative that further
intervention may be beneficial to identify all patients who meet NCCN criteria for a referral
for genetic counseling. This information is expected to improve protocols internally at
Prisma Health-Midlands. The genetic counselors plan to collaborate and provide updated
questionnaires to be used by the breast surgeons to include more of the NCCN criteria in
hopes of identifying more family history information prior to the breast conference. Further
studies can build upon the data from this study to assess success of interventions and impact
on patient care.
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APPENDIX A:
FAMILY HISTORY QUESTIONNAIRE

Figure A.1 First page of family history questionnaire
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Figure A.2 Second page of family history questionnaire
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